FIELD: medicine.
SUBSTANCE: invention refers to medicine, specifically to cardiology and concerns treating the patients suffering chronic cardiac failure. The method involves administering pharmacologically active relaxin H2 in a therapeutically effective amount equal to 10-480 mcg/kg a day. An indication for adding relaxin to the conducted therapy is chronic and stable compensated congestive cardiac failure at the moment of the beginning of treatment.
EFFECT: method provides reducing a rate of decompensation, a rate or length of stay in hospital, a risk of as compared to no-relaxin treatment.
6 cl, 2 ex, 3 tbl, 13 dwg
